Europe - FRA:PFE - US7170811035 - Common Stock
Taking everything into account, PFE scores 5 out of 10 in our fundamental rating. PFE was compared to 51 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of PFE while its profitability can be described as average. PFE scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.22% | ||
ROE | 12.12% | ||
ROIC | 7.61% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 28.52% | ||
PM (TTM) | 16.84% | ||
GM | 73.96% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.97 | ||
Altman-Z | 2.13 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.16 | ||
Quick Ratio | 0.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.24 | ||
Fwd PE | 7.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 11.22 | ||
EV/EBITDA | 6.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 7.14% |
FRA:PFE (9/30/2025, 5:28:05 PM)
20.93
+0.61 (+3.03%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 7.14% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 7.24 | ||
Fwd PE | 7.65 | ||
P/S | 2.19 | ||
P/FCF | 11.22 | ||
P/OCF | 9.19 | ||
P/B | 1.57 | ||
P/tB | N/A | ||
EV/EBITDA | 6.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.22% | ||
ROE | 12.12% | ||
ROCE | 10.81% | ||
ROIC | 7.61% | ||
ROICexc | 8.26% | ||
ROICexgc | 38.29% | ||
OM | 28.52% | ||
PM (TTM) | 16.84% | ||
GM | 73.96% | ||
FCFM | 19.48% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.65 | ||
Debt/FCF | 4.97 | ||
Debt/EBITDA | 2.3 | ||
Cap/Depr | 40.51% | ||
Cap/Sales | 4.31% | ||
Interest Coverage | 5.77 | ||
Cash Conversion | 60.76% | ||
Profit Quality | 115.66% | ||
Current Ratio | 1.16 | ||
Quick Ratio | 0.85 | ||
Altman-Z | 2.13 |